Broodkruimel
Documenten en Media
Introducing the Treatment Hierarchy Question in Network Meta-Analysis
Introducing the Treatment Hierarchy Question in Network Meta-Analysis
Versie 1.0 Goedgekeurd- Documenttype
- EXTERNAL_DOCUMENT
- Extensie
- png
- Grootte
- 139 kB
- Gewijzigd
- 21-10-22 13:28 door mir mir
- Gemaakt
- 21-10-22 13:28 door mir mir
- Locatie
- PUBLIC
- Waarderingen
-
-
Versie 1.0Door mir mir, over 21-10-22 13:28Geen wijzigingslogboek
Samenvatting
Comparative effectiveness research using network meta-analysis can present a hierarchy of competing treatments, from the most to the least preferable option. However, in published reviews, the research question associated with the hierarchy of multiple interventions is typically not clearly defined. Here we introduce the novel notion of a treatment hierarchy question that describes the criterion for choosing a specific treatment over one or more competing alternatives. For example, stakeholders might ask which treatment is most likely to improve mean survival by at least 2 years, or which treatment is associated with the longest mean survival. We discuss the most commonly used ranking metrics (quantities that compare the estimated treatment-specific effects), how the ranking metrics produce a treatment hierarchy, and the type of treatment hierarchy question that each ranking metric can answer. We show that the ranking metrics encompass the uncertainty in the estimation of the treatment effects in different ways, which results in different treatment hierarchies. When using network meta-analyses that aim to rank treatments, investigators should state the treatment hierarchy question they aim to address and employ the appropriate ranking metric to answer it. Following this new proposal will avoid some controversies that have arisen in comparative effectiveness research.
Het COMPAR-EU project heeft financiering ontvangen van het Horizon 2020 onderzoeks- en innovatieprogramma van de Europese Unie in het kader van subsidie overeenkomst nummer 754936.
Houd er rekening mee dat dit de bètaversie van het COMPAR-EU-platform is. Het bevat nu de voltooide resultaten voor Diabetes Type 2 en gedurende de zomer van 2022 zullen de resultaten voor obesitas, COPD en hartfalen worden voltooid. Ook wordt het platform de komende maanden uitgebreid en verbeterd.